Analyst Price Target is $22.50
▲ +127.96% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Akouos in the last 3 months. The average price target is $22.50, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 127.96% upside from the last price of $9.87.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Akouos.
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.